Medicare Carriers Denying Self-Injectable Drug Coverage Despite Mandate
Medicare's South Carolina carrier is refusing coverage for enoxaparin (Aventis' Lovenox), dalteparin (Pharmacia Fragmin) and interferon (Schering-Plough's Intron A) because they can be self-administered, despite a 1999 Congressional mandate requiring coverage, a South Carolina oncologist reported to a May 18 HCFA Town Hall meeting.
You may also be interested in...
HCFA is planning to review the amount of discretion that should be allowed to Medicare carriers on the coverage decisions for self-administerable drugs that were available through Medicare before 1997.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011